Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuyu Capsule (舒郁胶囊) is a Traditional Chinese Medicine (TCM) candidate developed by the Qingdao Haichuan Innovative Natural Medicine Research Center for the treatment of depression. It is specifically indicated for patients presenting with the "liver qi stagnation" (肝气郁结) syndrome, a common diagnostic pattern in TCM associated with mood disorders. The drug is formulated as an oral capsule and has been evaluated in Phase IIa clinical trials (such as CTR20150008) to assess its efficacy and safety using the Hamilton Depression Rating Scale (HAMD) as a primary endpoint. As a natural medicine product, it likely functions through the synergistic effects of multiple botanical constituents targeting various pathways in the central nervous system and the neuroendocrine system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuyu Capsule.